VistaStem Therapeutics is the wholly owned subsidiary of VistaGen Therapeutics, Inc. (NASDAQ: VTGN). We are dedicated to applying our human pluripotent stem cell technology platform and CardioSafe 3D™, our customized in-vitro cardiac cell bioassay system, to predict potential heart toxicity of new chemical entities (NCEs) long before they are tested in preclinical animal studies and human clinical studies. Together with a select group of companies focused on predictive toxicology, we are utilizing CardioSafe 3D in the FDA's Comprehensive in-vitro Proarrhythmia Assay (CiPA) initiative designed to change the landscape of preclinical drug development by providing a more complete and accurate assessment of potential drug effects on cardiac risk. We are also leveraging our stem cell technology to discover, rescue, develop and commercialize new chemical entities (NCEs) for central nervous system diseases and other therapeutic areas, small molecule NCEs with potential as regenerative medicines, and cellular therapies across a range of cell types.